Login to Your Account



NeoRx Restructures, Drops STR To Focus On Picoplatin

By Karen Pihl-Carey


Tuesday, May 10, 2005
Development and regulatory challenges have prompted NeoRx Corp. to drop development of its lead cancer program, close a Texas manufacturing facility and reduce its work force by 40 percent, all in an effort to focus its resources on the chemotherapeutic agent Picoplatin. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription